



OPEN ACCESS

ORIGINAL ARTICLE

# Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria

Yu-Jen Fang,<sup>1</sup> Jyh-Ming Liou,<sup>2</sup> Chieh-Chang Chen,<sup>1,2</sup> Ji-Yuh Lee,<sup>1</sup> Yao-Chun Hsu,<sup>3</sup> Mei-Jyh Chen,<sup>2</sup> Ping-Huei Tseng,<sup>2</sup> Chien-Chuan Chen,<sup>2</sup> Chi-Yang Chang,<sup>3</sup> Tsung-Hua Yang,<sup>1</sup> Wen-Hsiung Chang,<sup>4</sup> Jeng-Yi Wu,<sup>5</sup> Hsiu-Po Wang,<sup>2</sup> Jiing-Chyuan Luo,<sup>6</sup> Jaw-Town Lin,<sup>2,7</sup> Chia-Tung Shun,<sup>8</sup> Ming-Shiang Wu,<sup>2</sup> for the Taiwan Gastrointestinal Disease and Helicobacter Consortium

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/gutjnl-2014-308114>).

For numbered affiliations see end of article.

## Correspondence to

Professor Ming-Shiang Wu, Department of Internal Medicine and Primary Care Medicine, National Taiwan University Hospital, National Taiwan University, College of Medicine, No. 7, Chung-Shan S. Road, Taipei 100, Taiwan; [mingshiang@ntu.edu.tw](mailto:mingshiang@ntu.edu.tw) and [010002@ntuh.gov.tw](mailto:010002@ntuh.gov.tw)

J-ML and M-SW contributed equally.

Received 25 July 2014

Revised 8 October 2014

Accepted 18 October 2014

## ABSTRACT

**Background and objective** Whether there is distinct pathogenesis in subgroups of functional dyspepsia (FD), the postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS) remains controversial. We aimed to identify the risk factors of FD and its subgroups in the Chinese population.

**Methods** Patients with dyspepsia and healthy subjects who underwent gastric cancer screening were enrolled in this multicentre study from 2010 to 2012. All patients were evaluated by questionnaire, oesophagoduodenoscopy, histological examination and *Helicobacter pylori* tests. Subgroups of FD were classified according to the Rome III criteria. Psychiatric stress was assessed by the short form Brief Symptom Rating Scale. CagA and VacA genotypes were determined by PCR.

**Results** Of 2378 patients screened for eligibility, 771 and 491 fulfilled the diagnostic criteria of uninvestigated dyspepsia and FD, respectively. 298 (60.7%) and 353 (71.9%) individuals were diagnosed with EPS and PDS, respectively, whereas 169 (34.4%) had the overlap syndrome. As compared with 1031 healthy controls, PDS and EPS shared some common risk factors, including younger age (OR 0.95; 99.5% CI 0.93 to 0.98), non-steroidal anti-inflammatory drugs (OR 6.60; 99.5% CI 3.13 to 13.90), anxiety (OR 3.41; 99.5% CI 2.01 to 5.77) and concomitant IBS (OR 6.89; 99.5% CI 3.41 to 13.94). By contrast, *H. pylori* (OR 1.86; 99.5% CI 1.01 to 3.45), unmarried status (OR 4.22; 99.5% CI 2.02 to 8.81), sleep disturbance (OR 2.56; 99.5% CI 1.29 to 5.07) and depression (OR 2.34; 99.5% CI 1.04 to 5.36) were associated with PDS. Moderate to severe antral atrophy and CagA positive strains were also more prevalent in PDS.

**Conclusions** Different risk factors exist among FD subgroups based on the Rome III criteria, indicating distinct aetiopathogenesis of the subdivisions that may necessitate different therapeutic strategies.

## INTRODUCTION

Functional dyspepsia (FD), a common but heterogeneous disease, remains a great burden to the health-care system.<sup>1–5</sup> Numerous pathophysiological mechanisms, such as delayed gastric emptying, impaired gastric accommodation to a meal,<sup>6–7</sup> visceral hypersensitivity to gastric distension,<sup>8–9</sup> *Helicobacter pylori* infection,<sup>10–13</sup> psychosocial factors and central nervous system dysfunction,<sup>14–16</sup>

## Significance of this study

### What is already known on this subject?

- Functional dyspepsia (FD) is heterogeneous in its aetiology, pathogenesis and treatment responses.
- FD has been subdivided into epigastric pain syndrome (EPS) and postprandial distress syndrome (PDS) by the Rome III Consensus in an attempt to guide therapy.
- The subdivision was based on post hoc analysis and warrants more clinical data from different ethnic populations to support the distinct aetiopathogenesis of the two subgroups.

### What are the new findings?

- PDS and EPS shared some common risk factors including younger age, non-steroidal anti-inflammatory drugs, anxiety and concomitant IBS.
- *H. pylori*, unmarried status, sleep disturbance, depression, and less coffee consumption were associated with PDS, but not with EPS.
- The association of *H. pylori* with PDS was probably attributed to the more severe gastric atrophy at the antrum and the higher prevalence of CagA positive *H. pylori* strains.

### How might it impact on clinical practice in the foreseeable future?

- Different risk factors exist for subgroups of FD based on the Rome III criteria, indicating the distinct aetiopathogenesis of the subdivisions of FD that might necessitate different therapeutic strategies.

and lifestyle factors have been shown to be involved in the pathogenesis of FD.<sup>17–20</sup> Due to its complexity in pathogenesis, treatment for FD remains a challenge in clinical practice.<sup>2–4 21 22</sup> Although several treatment strategies, including testing and treatment for *H. pylori*, use of proton pump inhibitors, prokinetic agents and antidepressants have been shown to be effective in FD, each strategy is only effective in a small proportion of patients with FD.<sup>2–4 21 22</sup>

**To cite:** Fang Y-J, Liou J-M, Chen C-C, et al. *Gut* Published Online First: [please include Day Month Year] doi:10.1136/gutjnl-2014-308114

In order to simplify the intricate heterogeneity of this symptom complex and to guide the treatment, the Rome III Consensus proposed the subdivision of FD into two subgroups: the epigastric pain syndrome (EPS) which is characterised by epigastric pain and burning, and the postprandial distress syndrome (PDS) which is characterised by postprandial fullness and early satiety.<sup>1–4</sup> However, the subdivision of EPS and PDS was based on post hoc factor analysis of epidemiologic and pathophysiological studies that used the Rome II definition without direct supporting scientific evidence.<sup>1–4</sup> Therefore, it is crucial to elucidate whether there are distinct aetiologies and pathogenesis underlying the two subdivisions.

However, relatively few studies have investigated the differential pathogenesis in subgroups of FD according to the Rome III definition.<sup>23–29</sup> Increased recruitment of eosinophils in the duodenum has been observed in patients with PDS, but not EPS, in several studies.<sup>4, 23, 24</sup> Shindo *et al*<sup>25</sup> showed that lower acylated ghrelin levels might result in delayed gastric emptying in patients with PDS, but not with EPS. By contrast, Haag *et al*<sup>26</sup> reported no difference in delayed gastric emptying between PDS and EPS, while Kusano *et al*<sup>27</sup> showed rapid gastric emptying in PDS. Although previous epidemiological studies and meta-analysis of randomised trials supported the association of *H. pylori* with FD, whether it has differential roles in EPS and PDS remains poorly understood.<sup>10–13</sup> Besides, few studies addressed the impact of severity of gastric inflammation in the EPS and PDS subgroups.<sup>13, 28</sup> Recently, distinct psychopathological and personality traits have been reported in patients with PDS and EPS.<sup>14, 15</sup> Aro *et al*<sup>14</sup> showed differential associations of anxiety with PDS, but not with EPS. We previously identified that PDS, but not EPS, was independently associated with psychopathological stress, specifically in somatisation, depression and phobia.<sup>15</sup> Nevertheless, we did not recruit healthy controls and were therefore not able to confirm the association of psychopathology with FD as a whole in that study.<sup>15</sup> Furthermore, we did not assess the role of *H. pylori* in FD.<sup>15</sup>

Accordingly, in the present study we aimed to comprehensively explore the pathophysiological mechanisms, including psychopathology traits, *H. pylori* infection, virulence genotypes of *H. pylori*, severity of gastric inflammation and lifestyle factors underlying the two distinct subgroup syndromes of FD.

## MATERIALS AND METHODS

### Setting and study subjects

This multicentre, prospective study was conducted at the National Taiwan University Hospital (NTUH) in northern Taiwan and its Yun-Lin Branch in mid-west Taiwan from January 2010 to May 2012. Although these two hospitals were referral centres in these two regions, patients can visit the two centres as open access clinics without referral from primary care physicians. Consecutive adult patients with dyspeptic symptoms at outpatient clinics were invited to be assessed with the standard Rome III diagnostic questionnaire. Consecutive asymptomatic subjects who underwent gastric cancer screening in the two hospitals were enrolled as healthy controls. All patients and controls underwent detailed history taking, including demographic data, lifestyle factors, and the 5-item Brief Symptom Rating Scale (BSRS-5), a validated short form of the BSRS for the evaluation of psychiatric distress and personality traits.<sup>30</sup> They also underwent oesophagogastroduodenoscopy (OGD) and laboratory check-up to exclude organic disease or other metabolic disorders. All subjects with the following conditions were excluded: (1) age less than 20 years; (2) presence of organic disorders such as ulcers (defined as mucosal defect of 3 mm or

greater), ulcer scar, erosive oesophagitis, Barrett's oesophagus and malignancy on OGD survey (however, patients with erosions (defined as mucosal defect less than 3 mm) were not excluded); (3) concurrent severe illness, including malignancy at any sites, diabetes mellitus, advanced chronic kidney disease, liver cirrhosis and porphyria; (4) history of abdominal surgery; (5) bleeding tendency or current use of anticoagulants; and (6) regular use of aspirin, non-steroidal anti-inflammatory drugs (NSAIDs) or proton pump inhibitors (PPI) for more than 1 month. The study protocol was approved by the institutional review boards of NTUH. Written informed consent was obtained from all patients prior to enrolment.

### Rome III diagnostic questionnaire and symptoms definition

The Chinese version of the questionnaire was translated from the original Rome III FD module. It was reviewed by three investigators (YCH, JML and MSW), and scrutinised by two native Chinese speakers without medical background to confirm the fidelity of translation and to ensure that the text was easy to read and understand.<sup>15</sup> Details of this questionnaire were described in our previous study.<sup>15</sup> In brief, the questionnaire consists of 18 questions, which allows the diagnosis of FD and its two subgroups, PDS and EPS, which may coexist by definition. FD was defined as the presence of postprandial fullness/early satiety or pain/burning more than once per week, in the last 3 months according to the Rome III criteria.<sup>1</sup> Patients with typical reflux symptoms (heartburn/acid regurgitation), defined as moderate and which occurred more than 2 days per week, were excluded according to the Rome III criteria.<sup>1</sup> Patients with endoscopically confirmed erosive oesophagitis were also excluded. Non-prominent reflux symptoms may coexist with dyspeptic symptoms. However, patients fulfilling the criteria for functional disorder of the gallbladder and sphincter of Oddi were excluded. Well trained research assistants interviewed the patients to help them complete the questionnaires. IBS was defined as the presence of abdominal pain or discomfort at least 3 days per month in the last 3 months, associated with at least two of the following bowel habit changes: stool frequency, stool form, or symptoms relieved after defaecation according to the Rome III criteria.<sup>1</sup>

### Determination *H. pylori* infection, virulence genotypes and severity of gastric inflammation

All patients underwent serology testing, histological examination, rapid urease test, and culture; the healthy controls underwent the <sup>13</sup>C-urea breath test (<sup>13</sup>C-UBT) to examine *H. pylori*. Individuals who fulfilled one of the following criteria were defined as having *H. pylori* infection: (1) a positive <sup>13</sup>C-UBT; (2) a positive culture; or (3) at least two positive findings among rapid urease test, histology and serum antibody. The severity of gastritis was graded by the updated Sydney Classification. The CagA gene and the VacA signal region (s1/2) and midregion (m1/2) mosaics were determined by PCR as described previously.<sup>31</sup>

### Evaluation of psychiatric distress and lifestyle factors

BSRS-5 consisted of five parameters—sleep disturbance, anxiety, hostility, depression and inferiority—and was a validated instrument to assess psychiatric distress and personality traits.<sup>30</sup> The internal consistency coefficients of BSRS-5 ranged from 0.77 to 0.90.<sup>30</sup> Demographic data and lifestyle factors (including occupation, marital status, blood type, body mass index, education level, exercise habits, vegetarians, medication history, cigarette smoking, and consumption of alcohol, betel nut, tea and coffee) were recorded in all patients and controls. Smoking was

divided into never and ever (including those who are smokers or who quit less 5 years ago). Alcohol drinking was divided into never/rare and regular drinking (more than once a week, and >40 g per week). Betel nut chewing was divided into never/rare and regular (including who were chewing or who quit less than 5 years ago). Habits of tea, coffee and exercise were divided into never/rare (less than three times a month) and regular (more than once a week). The different kinds and quantities of tea, coffee and exercise were all noted. We excluded patients who took NSAIDs/aspirin regularly (defined as more than three times per week). We also excluded non-regular users who had taken NSAIDs/aspirin for more than 10 days in the month prior to enrolment. Non-regular users who took NSAIDs/aspirin for less than 10 days in the month prior to enrolment were classified as 'ever' NSAIDs/aspirin recent consumption.

## STATISTICAL METHODS

Categorical data were compared using the  $\chi^2$  test or Fisher's exact test as appropriate. Continuous data were compared with Student's t test and expressed as mean (SD) or one-way analysis of variance (ANOVA) as appropriate. Logistic regression analysis was used to identify risk factors of uninvestigated dyspepsia, FD and its subgroups, as compared to healthy controls. Adjusted ORs and 95% CIs were calculated. Those with p values of less than 0.05 were further included in the multivariable logistic regression models. Multiple testing adjustment with the Holm method was applied for controlling type I error. All statistical tests were two-tailed and p values of less than 0.005 were considered significant after adjustment for multiple testing. Statistical analyses were performed using SPSS V12.0 for Windows.

## RESULTS

### Enrolment of patients with dyspepsia and controls

During the study period, 2378 patients with dyspeptic symptoms were screened for eligibility (figure 1). Among the 771 individuals who had uninvestigated dyspepsia for more than 3 months, 280 patients (36.3%) had organic lesions on OGD. Therefore, 491 patients met the diagnostic criteria of FD. Of the 1168 asymptomatic healthy subjects assessed for eligibility, 137 were excluded, because of a history of malignancy in 46, diabetes mellitus in 86, chronic kidney diseases in 2 and liver cirrhosis in 3. A total of 1031 asymptomatic healthy subjects were eligible as controls. Among the 491 patients with FD, 298 (60.7%) and 353 (71.9%) fulfilled the diagnosis of EPS and PDS, respectively. A total of 169 (34.4%) had symptoms compatible with both PDS and EPS, whereas 9 (1.8%) patients with FD did not fit the diagnostic criteria of either PDS or EPS. In addition, 124 (25.3%) reported concomitant non-prominent reflux symptoms. The frequency, severity and associated symptoms are summarised in table 1.

We performed logistic regression analysis to explore the risk factors of uninvestigated dyspepsia, FD and its subgroups. The results of univariate analysis are shown in online supplementary tables S1 and S2, whereas the adjusted ORs are presented in tables 2 and 3.

### Demographic characteristics among patients with FD and its subgroups

Women had an increased risk of FD (OR 2.01; 99.5% CI 1.16 to 3.47) and a slightly higher risk of uninvestigated dyspepsia (OR 1.52; 99.5% CI 0.98 to 2.38) (table 2). Subgroup analysis showed a trend of increased risk of pure PDS (OR 2.08; 99.5% CI 0.93 to 4.66), pure EPS (OR 2.26; 99.5% CI 0.94 to 5.44),

and overlap syndrome (OR 2.35; 99.5% CI 0.92 to 6.04) in women, but the differences were not significant after adjustment for multiple testing (table 3). Those who never married had an increased risk of pure PDS (OR 4.22; 99.5% CI 2.02 to 8.81) (table 3). Subjects with a higher education level (above college) had a reduced risk of both uninvestigated dyspepsia (OR 0.32; 99.5% CI 0.17 to 0.60) and FD (OR 0.42; 99.5% CI 0.20 to 0.88) (table 2). In the subgroup analysis, however, the association remained significant only in the overlap syndrome (OR 0.22; 99.5% CI 0.07 to 0.67), but not in pure PDS (OR 0.51; 99.5% CI 0.17 to 1.56) or pure EPS (OR 0.61; 99.5% CI 0.18 to 2.05) (table 3).

### Lifestyle factors among patients with FD and its subgroups

Consumption of betel nuts was associated with increased risk of both uninvestigated dyspepsia (OR 6.31; 99.5% CI 2.20 to 18.12) and FD (OR 4.55; 99.5% CI 1.30 to 15.91) (table 2). Subgroup analysis showed that betel nut chewing was only associated with the overlap syndrome (OR 6.11; 99.5% CI 1.24 to 30.22), but not with pure EPS (OR 5.92; 99.5% CI 0.85 to 41.21) or pure PDS (OR 1.97; 99.5% CI 0.30 to 12.86) (table 3). Consumption of coffee was associated with a lower risk of uninvestigated dyspepsia (OR 0.65; 99.5% CI 0.44 to 0.97) and a trend for an inverse association with FD (OR 0.66; 99.5% CI 0.41 to 1.04) (table 2). Subgroup analysis showed that coffee was inversely associated with pure PDS (OR 0.49; 99.5% CI 0.25 to 0.92), but not with pure EPS (OR 0.62; 99.5% CI 0.30 to 1.24) and overlap syndrome (OR 0.74; 99.5% CI 0.37 to 1.49) (table 3). Regular exercise was associated with a lower risk of uninvestigated dyspepsia (OR 0.51; 99.5% CI 0.35 to 0.74) but the association with FD was statistically less significant (OR 0.68; 99.5% CI 0.44 to 1.05) (table 2). It was unrelated to any subgroup of FD (table 3). Recent consumption of non-steroidal anti-inflammatory drugs (NSAIDs), but not aspirin, was associated with increased risk of both uninvestigated dyspepsia (OR 5.96; 99.5% CI 3.04 to 11.69) and FD (OR 6.60; 99.5% CI 3.13 to 13.90) (table 2). The associations remained significant for pure PDS (OR 5.30; 99.5% CI 1.87 to 15.05), pure EPS (OR 7.62; 99.5% CI 2.77 to 20.95) and overlap syndrome (OR 8.76; 99.5% CI 3.28 to 23.40) (table 3).

### Psychopathology and personality traits among patients with FD and its subgroups

Sleep disturbance was positively associated with both uninvestigated dyspepsia (OR 1.76; 99.5% CI 1.18 to 2.61) and FD (OR 1.72; 99.5% CI 1.09 to 2.73) (table 2). Subgroup analysis showed that it was associated with pure PDS (OR 2.56; 99.5% CI 1.29 to 5.07) and overlap syndrome (OR 3.10; 99.5% CI 1.41 to 6.81), but not with pure EPS (OR 0.73; 99.5% CI 0.35 to 1.51) (table 3). Anxiety was positively associated with both uninvestigated dyspepsia (OR 2.82; 99.5% CI 1.78 to 4.46) and FD (OR 3.41; 99.5% CI 2.01 to 5.77) (table 2), as well as different subtypes of FD, including pure PDS (OR 2.80; 99.5% CI 1.34 to 5.88), pure EPS (OR 2.88; 99.5% CI 1.21 to 6.79) and overlap syndrome (OR 4.36; 99.5% CI 1.84 to 10.34) (table 3). Depression was positively associated with both uninvestigated dyspepsia (OR 1.80; 99.5% CI 1.10 to 2.93) and FD (OR 1.92; 99.5% CI 1.10 to 3.33) (table 2). Subgroup analysis showed that it was associated with pure PDS (OR 2.34; 99.5% CI 1.04 to 5.36), but not with pure EPS (OR 1.82; 99.5% CI 0.74 to 4.49) and overlap syndrome (OR 1.81; 99.5% CI 0.74 to 4.40) (table 3). Hostility was not associated with uninvestigated dyspepsia, FD and its subgroups after multiple testing (tables 2 and 3). Inferiority was inversely associated with FD (OR 0.48; 99.5% CI




Figure 1 Flowchart of the study.

0.26 to 0.90) (table 2). Subgroup analysis found no significant association with any subtype (table 3).

#### *H. pylori*, virulence genotypes and severity of gastric inflammation among patients with FD and its subgroups

*H. pylori* infection was positively associated with both uninvestigated dyspepsia (OR 1.88; 99.5% CI 1.30 to 2.73) and FD (OR 1.60; 99.5% CI 1.03 to 2.48) (table 2). Subgroup analysis showed that *H. pylori* infection was associated with only pure PDS (OR 1.86; 99.5% CI 1.01 to 3.45), but not with pure EPS (OR 1.43; 99.5% CI 0.72 to 2.84) or overlap syndrome (OR 1.12; 99.5% CI 0.55 to 2.28) (table 3). The density of *H. pylori*,

severity of intestinal metaplasia, and infiltration of neutrophils and monocytes were not significantly different among the three subgroups (figure 2). However, there was a trend of more moderate and marked gastric atrophy at the antrum in the subgroup of pure PDS (figure 2). Among *H. pylori* infected patients, we observed a trend ( $p=0.044$ ) of more CagA positive strains in pure PDS (98.4%), as compared with pure EPS (89.1%) and the overlap syndrome (85.7%), as shown in table 4.

#### Overlap with other functional gastrointestinal disorders

IBS was significantly associated with uninvestigated dyspepsia (OR 6.09; 99.5% CI 3.12 to 11.91) and FD (OR 6.89; 99.5%

**Table 1** Symptom frequency, severity of subgroups of functional dyspepsia

Cardinal symptom	Pure PDS (n=184)			Pure EPS (n=129)	Pure overlap (n=169)			
	Postprandial fullness n (%)	Early satiation n (%)	Both* n (%)	Epigastric pain/burning n (%)	Postprandial fullness n (%)	Early satiation n (%)	Both* n (%)	Epigastric pain/burning n (%)
Frequency								
≥2 days/week	48 (26.1)	40 (21.7)	5 (2.6)	108 (83.7)	53 (31.4)	9 (5.3)	15 (8.9)	86 (50.9)
Every day	55 (29.9)	29 (15.7)	7 (3.8)	21 (16.3)	63 (37.3)	12 (7.1)	17 (10.0)	83 (49.1)
Severity								
Mild	54 (29.3)	29 (15.8)	6 (3.3)	61 (47.3)	39 (30.2)	10 (5.9)	10 (5.9)	58 (34.3)
Moderate	40 (21.7)	21 (11.4)	4 (2.1)	55 (42.6)	63 (48.8)	7 (4.1)	17 (10.1)	89 (52.7)
Severe	9 (4.9)	7 (3.8)	2 (1.1)	13 (10.1)	14 (10.6)	4 (2.4)	5 (3.0)	22 (13.0)
Associated symptoms								
Nausea	6 (3.3)	3 (1.6)	9 (4.9)	5 (3.9)	11 (6.5)	1 (0.6)	7 (4.1)	9 (5.3)
Belching	5 (2.7)	3 (1.6)	6 (3.3)	3 (2.30)	9 (5.3)	1 (0.6)	6 (3.6)	7 (4.1)
Bloating	66 (35.9)	45 (24.5)	9 (4.9)	30 (23.2)	86 (50.9)	11 (6.5)	18 (10.7)	41 (24.3)
Non-prominent reflux	31 (16.8)	18 (9.8)	5 (2.7)	28 (21.7)	25 (14.8)	15 (8.9)	2 (1.2)	42 (24.9)

Nine unspecific subgroup subjects were not included.

\*Both, subjects had typical symptom of postprandial fullness and early satiation. EPS, epigastric pain syndrome; PDS, postprandial distress syndrome.

CI 3.41 to 12.94) (table 2). Subgroup analysis showed that it was associated with the three subgroups of FD: pure PDS (OR 5.90; 99.5% CI 2.53 to 14.66), pure EPS (OR 7.43; 99.5% CI 2.80 to 19.73) and overlap syndrome (OR 7.19; 99.5% CI 2.72 to 19.01) (table 3). Of the 141 FD subjects with concomitant IBS (including 26 constipation-predominant, 42 diarrhoea-predominant, 30 mixed-type, and 43 un-subtyped), the proportions of subtypes of IBS in FD were similar ( $p=0.25$ ).

## DISCUSSION

There are several novel findings in the present study. We found that PDS and EPS shared common risk factors, including younger age, NSAIDs consumption, anxiety and concomitant IBS. Interestingly, we identified several risk factors distinct for PDS but not EPS, including *H. pylori* infection (OR 1.86 99.5% CI 1.01 to 3.45), unmarried status (OR 4.22 99.5% CI 2.02 to 8.81), sleep disturbance (OR 2.56 99.5% CI 1.29 to 5.07) and depression (OR 2.34 99.5% CI 1.04 to 5.36). Coffee consumption (OR 0.49 99.5% CI 0.25 to 0.92) was protective against PDS, but not EPS. We further showed that the association of *H. pylori* infection with PDS was probably mediated through the severity of gastric atrophy at the antrum. Interestingly, we also observed a higher prevalence of CagA positive *H. pylori* strains in PDS. These results collectively indicated that a distinct aetiopathogenesis underlies the subdivisions of FD according to the Rome III criteria.

The association of *H. pylori* with FD and its subgroups according to the Rome III criteria has been reported with inconsistent results in several observational studies.<sup>13 14 17</sup> Aro *et al*<sup>14</sup> and Zagari *et al*<sup>17</sup> found no significant association of *H. pylori* with FD in Western populations. Meta-analysis of randomised control trials revealed a small but significant reduction in dyspeptic symptoms after *H. pylori* eradication and the number needed to treat to cure was 14.<sup>11 13</sup> Of the six trials that addressed the differential impacts of *H. pylori* eradication on symptom relief according to subgroups of FD,<sup>12 32–36</sup> only two studies applied the Rome III definition.<sup>12 36</sup> Of the three trials that showed a benefit of *H. pylori* eradication on FD, there were no significant differences between subgroups.<sup>12 34 35</sup> By

contrast, Lan *et al*<sup>36</sup> reported a significant effect only in the EPS subgroup. The contradictory results might result from differences in the definitions of subgroups, efficacies of eradication regimens, *H. pylori* infection prevalence and the ethnic groups.<sup>13</sup> Further well designed randomised control trials are eagerly anticipated to assess whether therapeutic responses to *H. pylori* eradication differ according subgroups of FD.

There are several possible explanations for the different association of *H. pylori* infection with PDS and EPS. First, the higher prevalence of more virulent *H. pylori* strains in PDS might be contributory. This study found a higher prevalence of CagA positive *H. pylori* infection, which might account for more severe atrophic changes of the antrum, in patients with PDS. Second, the bacterial components and toxins of *H. pylori* infection might directly activate the peripheral sensory neurons and enhance the visceral hypersensitivity. This hypothesis was supported by a previous study which showed exaggerated postprandial gastric distension in *H. pylori* infected patients (80%), as compared with uninfected patients (33%).<sup>37</sup> Although we found an association of *H. pylori* with PDS in a hospital-based study in Taiwan, where the prevalence of *H. pylori* infection and CagA positive strains remains high, a further population-based study is warranted to estimate the relationship between *H. pylori* and FD in Asian populations.

The association of FD with psychopathology and personality traits has been reported in several studies.<sup>4 16</sup> However, randomised trials failed to demonstrate consistent beneficial effects of anxiolytic agents or antidepressants, probably related to its heterogeneous aetiopathogenesis.<sup>38</sup> We found a significant association between depression and PDS, similar to the findings by Clauwaert *et al*<sup>39</sup> and Handa *et al*.<sup>40</sup> However, this was contradictory to a population-based study.<sup>14</sup> We also observed a higher prevalence of sleep disturbance in PDS, but not in EPS. This result was consistent with previous hospital-based studies, but was not found in population-based research.<sup>41–43</sup> By contrast, Yamawaki *et al* reported that sleep disturbance was similar in patients with EPS and those with PDS.<sup>44</sup> These inconsistent findings might be attributed to differences in the study population (eg, hospital vs community, East vs West), assessment tools,

**Table 2** Risk factors of uninvestigated dyspepsia and functional dyspepsia as compared with healthy controls; multivariate analysis

	No dyspepsia (n=1031)		Uninvestigated dyspepsia (n =771)			Functional dyspepsia (n=491)		
	n (%)	n (%)	OR (99.5% CI)	p Value	n (%)	OR (99.5% CI)	p Value	
<i>Demographic factors</i>								
<i>Sex</i>								
Male	515 (50.0)	302 (39.2)	1	0.008	146 (29.7)	1	<0.001	
Female	516 (50.0)	469 (60.8)	1.52 (0.98 to 2.38)		345 (70.3)	2.01 (1.16 to 3.47)		
<i>Age (years)</i>								
Mean (SD)	51.79 (10.69)	46 (13.80)	0.96 (0.94 to 0.98)	<0.001	45.0 (13.30)	0.95 (0.93 to 0.98)	<0.001	
<i>Occupation</i>								
Unemployed	354 (34.3)	250 (32.4)	1	0.786	168 (34.2)	1	0.478	
White-collar	372 (36.1)	246 (31.9)	0.95 (0.61 to 1.49)	0.763	170 (34.6)	1.05 (0.63 to 1.75)	0.795	
Labourer	305 (29.1)	275 (35.7)	0.89 (0.55 to 1.43)	0.490	153 (31.2)	0.84 (0.48 to 1.47)	0.375	
<i>Married status</i>								
Married	937 (90.9)	620 (80.4)	1	0.107	384 (78.2)	1	0.147	
Never married	94 (9.1)	151 (19.6)	1.42 (0.77 to 2.64)		107 (21.8)	1.42 (0.72 to 2.80)		
<i>Education level</i>								
Below elementary	102 (9.9)	124 (16.1)	1		60 (12.2)	1		
Below senior high school	252 (24.4)	312 (40.5)	0.77 (0.42 to 1.41)	0.228	193 (39.3)	0.95 (0.46 to 1.97)	0.831	
Above college	677 (65.7)	335 (43.5)	0.32 (0.17 to 0.60)	<0.001	238 (48.5)	0.42 (0.20 to 0.88)	0.001	
<i>Lifestyle factors</i>								
<i>BMI (kg/m<sup>2</sup>)</i>								
Mean (SD)	23.52 (3.19)	23.72 (7.63)	1.02 (0.99 to 1.06)	0.081	22.94 (5.10)	1.00 (0.95 to 1.05)	0.872	
<i>Smoking</i>								
Never	831 (80.6)	545 (70.7)	1	0.032	381 (77.6)	1	0.284	
Ever	200 (19.4)	226 (29.3)	1.49 (0.88 to 2.51)		110 (22.4)	1.28 (0.68 to 2.41)		
<i>Alcohol consumption</i>								
Never	842 (81.7)	558 (72.4)	1	0.063	378 (77.0)	1	0.216	
Ever	189 (18.3)	213 (27.6)	1.38 (0.85 to 2.24)		113 (23.0)	1.29 (0.73 to 2.29)		
<i>Betel nut chewing</i>								
Never	1017 (98.6)	683 (88.6)	1	<0.001	452 (92.1)	1	0.001	
Ever	14 (1.4)	88 (11.4)	6.31 (2.20 to 18.12)		39 (7.9)	4.55 (1.30 to 15.91)		
<i>Tea consumption</i>								
Never	461 (44.7)	383 (49.7)	1	0.302	247 (50.3)	1	0.213	
Ever	570 (55.3)	388 (50.3)	0.87 (0.59 to 1.28)		244 (49.7)	0.82 (0.52 to 1.29)		
<i>Coffee consumption</i>								
Never	545 (52.9)	479 (62.1)	1	0.002	297 (60.5)	1	0.011	
Ever	486 (47.1)	292 (37.9)	0.65 (0.44 to 0.97)		194 (39.5)	0.66 (0.41 to 1.04)		
<i>Vegetarian</i>								
Never	996 (96.9)	724 (93.9)	1	0.106	462 (94.1)	1	0.319	
Ever	35 (3.4)	47 (6.1)	1.62 (0.70 to 3.73)		29 (5.9)	1.41 (0.53 to 3.73)		
<i>Exercise habit</i>								
Less/never	361 (35.0)	488 (63.3)	1	<0.001	297 (60.5)	1	0.012	
Ever	670 (65.0)	283 (36.7)	0.51 (0.35 to 0.74)		194 (39.5)	0.68 (0.44 to 1.05)		
<i>NSAIDs recent consumption</i>								
Never	997 (96.7)	598 (77.6)	1	<0.001	383 (78.0)	1	<0.001	
Ever	34 (3.3)	173 (22.4)	5.96 (3.04 to 11.69)		108 (22.0)	6.60 (3.13 to 13.90)		
<i>Aspirin recent consumption</i>								
Never	997 (96.7)	761 (98.7)	1	0.072	484 (98.6)	1	0.343	
Ever	34 (3.3)	10 (1.3)	0.43 (0.11 to 1.61)		7 (1.4)	0.61 (0.14 to 2.68)		
<i>Psychological factors (BSRS-5)</i>								
<i>I. Sleep disturbance</i>								
No	619 (60.0)	280 (36.3)	1	<0.001	161 (32.8)	1	0.001	
Yes	412 (40.0)	491 (63.7)	1.76 (1.18 to 2.61)		330 (67.2)	1.72 (1.09 to 2.73)		
<i>II. Anxiety</i>								
No	727 (70.5)	321 (41.6)	1	<0.001	169 (34.4)	1	<0.001	
Yes	304 (29.5)	450 (58.4)	2.82 (1.78 to 4.46)		332 (64.8)	3.41 (2.01 to 5.77)		
<i>III. Hostility</i>								
No	674 (65.4)	376 (48.8)	1	0.021	214 (43.6)	1	0.176	
Yes	357 (34.6)	395 (51.2)	0.67 (0.41 to 1.09)		277 (56.4)	0.76 (0.44 to 1.34)		

Continued

Table 2 Continued

	No dyspepsia (n=1031)		Uninvestigated dyspepsia (n =771)			Functional dyspepsia (n=491)		
	n (%)	n (%)	OR (99.5% CI)	p Value	n (%)	OR (99.5% CI)	p Value	
IV. Depression								
No	759 (73.6)	389 (50.5)	1	0.001	225 (45.8)	1	0.001	
Yes	272 (26.4)	382 (49.5)	1.80 (1.10 to 2.93)		266 (54.2)	1.92 (1.10 to 3.33)		
V. Inferiority								
No	891 (86.4)	579 (75.1)	1	0.007	366 (74.5)	1	0.001	
Yes	140 (13.6)	192 (24.9)	0.59 (0.34 to 1.02)		125 (25.5)	0.48 (0.26 to 0.90)		
Other factors								
<i>H. pylori</i>								
No	652 (63.2)	413 (53.6)	1	<0.001	295 (60.1)	1	0.003	
Yes	379 (36.8)	358 (46.4)	1.88 (1.30 to 2.73)		196 (39.9)	1.60 (1.03 to 2.48)		
IBS								
No	999 (96.9)	620 (80.4)	1	<0.001	347 (70.7)	1	<0.001	
Yes	32 (3.1)	151 (19.6)	6.09 (3.12 to 11.91)		144 (29.3)	6.89 (3.41 to 13.94)		

ORs and 99.5% CIs calculated using a multivariate logistic regression model adjusted for all variables of p values less than 0.05 in the online supplementary table S1 and multiple testing adjustment (Holm method).

BMI, body mass index; BSR5-5, 5-item Brief Symptom Rating Scale; IBS, irritable bowel syndrome.

and ethnic and cultural differences. Nevertheless, these studies collectively showed that subgroups of FD differ in the association with psychological stress.

The mechanism underpinning the link with psychopathology remains poorly understood, but there are several plausible explanations. Perturbation of brain-gut signalling, including impaired sensory filtering, impaired cognitive circuits, or impaired descending modulatory system to physiological and salient/noxious stimuli, might be impaired by psychosocial factors, which in turn leads to impaired descending modulatory pathways.<sup>16</sup> Dysfunction of the autonomic nervous system, including hyperactive sympathetic tone and hypoactive vagal counterpart,<sup>45</sup> might lead to visceral hypersensitivity and cause dyspeptic symptoms. Some pathophysiological studies reported that impaired gastric accommodation was more common in patients with PDS than those with EPS.<sup>4</sup> Therefore, it is possible that the autonomic dysfunction associated with depression might impair gastric accommodation and produce symptoms of PDS.<sup>45</sup> Nevertheless, the results from our study led us to propose the hypothesis that antidepressants might be more effective in the subgroup with PDS. Further interventional trials are eagerly anticipated to prove this hypothesis.

Recent studies showed that the Rome III criteria cannot distinguish patients with organic diseases from those with FD.<sup>46-47</sup> Our study had similar results, reporting that 36.3% (280/771) of cases of uninvestigated dyspepsia had structural lesions on OGD. More importantly, we also observed a significant overlap (n=169, 34.4%) among patients diagnosed with PDS and those with EPS. Whereas the EPS and PDS syndromes can be discriminated better in population-based studies, significant overlap was observed in hospital-based studies.<sup>4</sup> This indicated that the proportion of overlap might increase with disease severity and it is important to clarify whether those with the overlap syndrome have distinct pathogenesis. By revealing the association with NSAIDs, anxiety and IBS, our study showed that the overlap syndrome shared similar risk factors with pure EPS and pure PDS.

The impact of NSAIDs consumption on the risk of FD remains controversial. Our result agreed with Aro *et al*<sup>14</sup> that NSAIDs might influence the risk of FD and its subgroups. However, it has recently been shown that enteropathy can be

detected by capsule endoscopy in 50–68% of NSAID users.<sup>48</sup> Therefore, some patients with 'FD' who have recently taken NSAIDs may actually have enteral lesions that are not detected on OGD. Besides, we found an interesting association of betel nut chewing with FD and the overlap subgroup. Betel nut chewing is a unique culture in Asia and has been shown to be a causal factor of squamous cell carcinoma of the oral cavity, oropharynx and oesophagus.<sup>49</sup> Interpretation of this association requires caution, particularly when the educational level is significantly lower in patients with FD. Since the habit of betel nut chewing is more common in blue-collar labourers than in white-collar workers, it could be a surrogate marker indicating low socioeconomic status (SES). Nevertheless, the association remained significant after adjustment for education and occupation, both of which could also stand for the SES. Besides, the association was significant for pure EPS and overlap syndrome, but not for pure PDS, indicating that this association was not related to lower SES alone. Clearly, this finding warrants further study for confirmation. Whether the association is directly related to the noxious stimuli of betel nuts or secondary to perturbation in visceral hypersensitivity needs to be clarified in future studies. The interesting protective effect of coffee consumption in PDS was probably related to the accelerated gastric emptying time of coffee.<sup>50-51</sup> However, interventional trials are necessary to prove this hypothesis. We did not find an association between tea and FD in the present study. However, future studies are warranted to assess whether different kinds of tea have different biological effects in the pathogenesis of FD.

The strengths of this study included a large sample size, comprehensive analysis of each risk factors and endoscopic examination in all participants. We also assessed *H. pylori* status, its virulence genotypes and histological changes to explore the pathogenesis in different subgroups of FD. Nevertheless, there were some limitations. First, this was a hospital-based study which cannot be representative of the general population. However, the aim of the study is to analyse the risk factors of FD and its subgroups rather than to report the prevalence in the general population. Second, histological examination was not done in healthy controls. Nevertheless, this limitation did not compromise the finding that gastric atrophy was more severe in PDS patients than their EPS counterparts. Third, *H. pylori*

**Table 3** Risk factors of subgroups of functional dyspepsia as compared with healthy controls; multivariate analysis

	No dyspepsia (n=1031) n (%)	Pure PDS (n=184)			Pure EPS (n=129)			Pure overlap (n=169)		
		n (%)	OR (99.5% CI)	p Value	n (%)	OR (99.5% CI)	p Value	n (%)	OR (99.5% CI)	p Value
<i>Demographic factors</i>										
<i>Sex</i>										
Male	515 (50.0)	55 (29.9)	1	0.011	41 (31.8)	1	0.009	47 (27.8)	1	0.011
Female	516 (50.0)	129 (70.1)	2.08 (0.93 to 4.66)		88 (68.2)	2.26 (0.94 to 5.44)		122 (72.2)	2.35 (0.92 to 6.04)	
<i>Age</i>										
Mean (SD)	51.79 (10.69)	44 (13.83)	0.94 (0.91 to 0.97)	<0.001	46 (13.12)	0.96 (0.93 to 1.00)	0.005	44 (12.87)	0.95 (0.91 to 0.98)	<0.001
<i>Occupation</i>										
Unemployed	354 (34.3)	55 (29.9)	1	0.229	39 (30.2)	1	0.043	72 (42.6)	1	0.415
White-collar	372 (36.1)	74 (40.2)	1.48 (0.71 to 3.08)	0.139	46 (35.7)	0.54 (0.24 to 1.20)	0.031	46 (27.2)	1.45 (0.63 to 3.31)	0.211
Labourer	305 (29.1)	55 (29.9)	1.03 (0.46 to 2.32)	0.929	44 (34.1)	0.52 (0.22 to 1.25)	0.037	51 (30.2)	1.39 (0.403.77)	0.287
<i>Married</i>										
Yes	937 (90.9)	130 (71.0)	1	<0.001	103 (79.8)	1	0.610	138 (86.7)	1	0.882
Never	94 (9.1)	53 (29.0)	4.22 (2.02 to 8.81)		20 (15.5)	1.23 (0.40 to 3.77)		31 (18.3)	1.06 (0.37 to 3.02)	
<i>Education</i>										
Below elementary	102 (9.9)	18 (9.8)	1		17 (13.2)	1		23 (13.6)	1	
Below senior high school	252 (24.4)	67 (36.4)	1.19 (0.39 to 3.60)	0.658	49 (38.0)	1.23 (0.37 to 4.09)	0.629	75 (44.4)	0.70 (0.24 to 2.02)	0.339
Above college	677 (65.7)	99 (53.8)	0.51 (0.17 to 1.56)	0.092	63 (48.8)	0.61 (0.18 to 2.05)	0.250	71 (42.0)	0.22 (0.07 to 0.67)	<0.001
<i>Blood type*</i>										
A type	264 (25.6)	44 (26.3)	1		30 (27.8)	1		46 (31.5)	1	
B type	223 (21.6)	42 (25.1)	1.05 (0.45 to 2.46)	0.879	27 (25.0)	1.17 (0.46 to 2.97)	0.640	25 (17.1)	0.782 (0.30 to 2.24)	0.580
AB type	56 (5.4)	15 (9.0)	1.68 (0.50 to 5.63)	0.230	5 (4.6)	1.53 (0.33 to 7.13)	0.438	22 (15.1)	3.79 (1.15 to 12.48)	0.002
O type	435 (42.2)	66 (39.5)	0.75 (0.36 to 1.60)	0.290	46 (42.6)	0.91 (0.40 to 2.04)	0.738	53 (36.3)	0.88 (0.39 to 1.99)	0.663
<i>Lifestyle factors</i>										
<i>BMI (kg/m<sup>2</sup>)</i>										
Mean (SD)	23.52 (3.19)	22.55 (3.60)	0.98 (0.89 to 1.09)	0.633	23.83 (7.63)	1.04 (0.98 to 1.11)	0.081	22.74 (4.02)	0.95 (0.85 to 1.05)	0.134
<i>Smoking</i>										
Never	831 (80.6)	144 (78.3)	1	0.731	105 (81.4)	1	0.679	124 (73.4)	1	0.057
Ever	200 (19.4)	40 (21.7)	1.12 (0.44 to 2.86)		24 (18.6)	0.85 (0.28 to 2.58)		45 (26.6)	2.00 (0.72 to 5.56)	
<i>Alcohol consumption</i>										
Never	842 (81.7)	138 (75.0)	1	0.036	105 (81.4)	1	0.785	128 (75.7)	1	0.296
Ever	189 (18.3)	46 (25.0)	1.80 (0.82 to 3.97)		24 (18.6)	1.10 (0.42 to 2.88)		41 (24.3)	1.41 (0.56 to 3.52)	
<i>Betel nut</i>										
Never	1017 (98.6)	174 (94.6)	1	0.313	120 (93.0)	1	0.010	150 (88.8)	1	0.001
Ever	14 (1.4)	10 (5.4)	1.97 (0.30 to 12.86)		9 (7.0)	5.92 (0.85 to 41.21)		19 (11.2)	6.11 (1.24 to 30.22)	
<i>Coffee</i>										
Never	545 (52.9)	119 (64.7)	1	0.002	75 (58.1)	1	0.053	96 (56.8)	1	0.227
Ever	486 (47.1)	65 (35.3)	0.49 (0.25 to 0.92)		54 (41.9)	0.62 (0.30 to 1.24)		73 (43.2)	0.74 (0.37 to 1.49)	
<i>Exercise habit</i>										
Less/never	361 (35.0)	105 (57.1)	1	0.206	80 (62.0)	1	0.124	106 (62.7)	1	0.012
Ever	670 (65.0)	79 (42.9)	0.76 (0.41 to 1.41)		49 (38.0)	0.69 (0.35 to 1.36)		63 (37.3)	0.54 (0.27 to 1.07)	

Continued




Table 3 Continued

	No dyspepsia (n=1031)			Pure PDS (n=184)			Pure EPS (n=129)			Pure overlap (n=169)		
	n (%)	n (%)	OR (99.5% CI)	p Value	n (%)	OR (99.5% CI)	p Value	n (%)	OR (99.5% CI)	p Value		
NSAIDs recent used												
Never	997 (96.7)	151 (82.1)	1	<0.001	99 (76.4)	1	<0.001	125 (74.0)	1	<0.001		
Ever	34 (3.3)	33 (17.9)	5.30 (1.87 to 15.05)		30 (23.3)	7.62 (2.77 to 20.95)		44 (26.0)	8.76 (3.28 to 23.40)			
<i>Psychological factors (BSRS-5)</i>												
I. Sleep disturbance												
No	619 (60.0)	47 (25.5)	1	<0.001	72 (55.8)	1	0.221	39 (23.1)	1	<0.001		
Yes	412 (40.0)	137 (74.5)	2.56 (1.29 to 5.07)		57 (44.2)	0.73 (0.35 to 1.51)		130 (76.9)	3.10 (1.41 to 6.81)			
II. Anxiety												
No	727 (70.5)	56 (30.4)	1	<0.001	57 (44.2)	1	0.001	53 (31.4)	1	<0.001		
Yes	304 (29.5)	128 (69.6)	2.80 (1.34 to 5.88)		72 (55.8)	2.88 (1.21 to 6.79)		116 (68.6)	4.36 (1.84 to 10.34)			
III. Hostility												
No	674 (65.4)	72 (39.1)	1	0.118	61 (47.3)	1	0.924	74 (43.8)	1	0.091		
Yes	357 (34.6)	112 (60.9)	0.63 (0.28 to 1.44)		68 (52.7)	1.03 (0.41 to 2.60)		95 (56.2)	0.58 (0.23 to 1.48)			
IV. Depression												
No	759 (73.6)	74 (40.2)	1	0.003	66 (51.2)	1	0.062	79 (46.7)	1	0.063		
Yes	272 (26.4)	110 (59.8)	2.34 (1.04 to 5.36)		63 (48.8)	1.82 (0.74 to 4.49)		90 (53.3)	1.81 (0.74 to 4.40)			
V. Inferiority												
No	891 (86.4)	134 (72.8)	1	0.070	99 (76.7)	1	0.009	126 (74.6)	1	0.008		
Yes	140 (13.6)	50 (27.2)	0.58 (0.24 to 1.36)		30 (23.3)	0.38 (0.13 to 1.08)		43 (25.4)	0.40 (0.15 to 1.06)			
<i>Other factors</i>												
<i>H. pylori</i>												
No	652 (63.2)	102 (55.4)	1	0.005	77 (59.7)	1	0.148	110 (65.1)	1	0.646		
Yes	379 (36.8)	82 (44.6)	1.86 (1.01 to 3.45)		50 (40.3)	1.43 (0.72 to 2.84)		59 (34.9)	1.12 (0.55 to 2.28)			
IBS												
No	999 (96.9)	129 (70.1)	1	<0.001	96 (74.4)	1	<0.001	116 (68.6)	1	<0.001		
Yes	32 (3.1)	55 (29.9)	5.90 (2.53 to 14.66)		33 (25.6)	7.43 (2.80 to 19.73)		53 (31.4)	7.19 (2.72 to 19.01)			

ORs and 99.5% CIs calculated using a multivariate logistic regression model adjusted for all variables of p values less than 0.05 in the online supplementary table S2 and multiple testing adjustment (Holm method).

\*Blood type was unknown in 53 with control group, 17 with PDS, 23 with EPS, 25 with overlap syndrome.

BMI, body mass index; BSRS-5, 5-item Brief Symptom Rating Scale; EPS, epigastric pain syndrome; PDS, postprandial distress syndrome.



**Figure 2** Severity of gastritis reported according to the Sydney classification. \*Comparison among three distinct groups. †H. pylori infected group: Sydney classification of the body unknown in 25. ‡Non-H. pylori group: Sydney classification of the body unknown in 19.

**Table 4** Prevalence of virulence genotypes in subgroups of functional dyspepsia among *H. pylori* infected patients

	Pure PDS % (n)	Pure EPS % (n)	Pure overlap % (n)	p Value
CagA				0.044
Positive	98.4% (60/61)	89.1% (41/46)	85.7% (42/49)	
Negative	1.6% (1/61)	10.9% (5/46)	14.3% (7/49)	
VacA				0.749
S1	95.1% (58/61)	97.9% (46/47)	95.8% (46/48)	
S2	4.9% (3/61)	2.1% (1/47)	4.2% (2/48)	
VacA				0.318
M1	60.0% (36/60)	45.5% (20/44)	56.9% (29/51)	
M2	40.0% (24/60)	54.5% (24/44)	17.6% (9/51)	

p Values calculated using  $\chi^2$  test or Fisher's exact test as appropriate. EPS, epigastric pain syndrome; PDS, postprandial distress syndrome.

status was determined by UBT alone in healthy controls, whereas FD patients underwent rapid urease test, histological examination, culture and serology. However,  $^{13}\text{C}$ -UBT alone is accurate in the diagnosis of *H. pylori* infection.<sup>52</sup> Another limitation was that income was not included in our analysis, although we did include occupation and education levels as markers of SES. In this study, we used the BSRS rather than HADs to quantify anxiety and depression, which might limit the comparability with other studies. However, we chose this instrument because it has been validated in our population. In this study, non-regular users who took NSAIDs/aspirin for less than 10 days in the month prior to enrolment were not excluded. Since NSAIDs/aspirin may also cause dyspepsia, patients who were taking NSAIDs/aspirin were excluded in some studies. However, patients taking NSAIDs/aspirin were not excluded in some population-based studies.<sup>14–17</sup> Therefore, we did not exclude those who took NSAIDs/aspirin for less than 10 days in the month prior to enrolment. Finally, this is a cross-sectional study which cannot establish causal relationships. Further cohort studies and interventional trials are anticipated to test the hypotheses generated from this study.

In conclusion, PDS and EPS shared some common risk factors, including younger age, NSAIDs consumption, anxiety and IBS. However, PDS, but not EPS, was associated with *H. pylori* and psychological stress, including sleep disturbance and depression. We further demonstrated that the different association of *H. pylori* with PDS was probably mediated through more severe gastric atrophy at the antrum and higher prevalence of CagA positive *H. pylori* infection. In addition, coffee consumption was protective against PDS but not EPS. Our results collectively implicate the presence of distinct aetiopathogenesis in the subdivisions of FD according to the Rome III criteria. Further randomised control trials are eagerly anticipated to test whether the therapeutic responses to *H. pylori* eradication and antidepressants differ according to the FD subgroup.

#### Author affiliations

<sup>1</sup>Department of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, Douliou, Taiwan

<sup>2</sup>Department of Internal Medicine, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan

<sup>3</sup>Department of Internal Medicine, E-DA Hospital and I-Shou University, Kaohsiung County, Taiwan

<sup>4</sup>Division of Gastroenterology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan

<sup>5</sup>Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

<sup>6</sup>Department of Medicine, National Yang-Ming University, School of Medicine, and Taipei Veterans General Hospital, Taipei, Taiwan

<sup>7</sup>School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan

<sup>8</sup>Department of Pathology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan

**Acknowledgements** We would like to express our special thanks to the staff of the Eighth Core Lab, Department of Medical Research, National Taiwan University Hospital and the Bioinformatics Consortium of Taiwan, National Core Facility Program for Biotechnology (NSC 100-2319-B-010-002) for technical support in this study.

**Contributors** Study concept and design: Y-JF, J-ML, C-CC, M-SW; acquisition of data: Y-JF, J-ML, C-CC, J-YL, Y-CH, M-JC, P-HT, C-CC, C-YC, T-HY, W-HC, J-YW and J-CL; drafting of the manuscript: Y-JF and J-ML; critical revision of the manuscript for important intellectual content: M-SW; statistical analysis: Y-JF; study supervision: J-TL, C-TS, M-SW.

**Funding** The study was funded by the National Clinical Trial Center of National Taiwan University Hospital and the National Science Council, Executive Yuan, ROC, Taiwan (Grant Number: NSC 102-2325-B-002 -084).

**Competing interests** None.

**Patient consent** Obtained.

**Ethics approval** National Taiwan University Hospital.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

#### REFERENCES

- Tack J, Talley NJ, Camilleri M, *et al.* Functional gastroduodenal disorders. *Gastroenterology* 2006;130:1466–79.
- Ford AC, Moayyedi P. Dyspepsia. *BMJ* 2013;347:f5059.
- Ghoshal UC, Singh R, Chang FY, *et al.* Functional Dyspepsia Consensus Team of the Asian Neurogastroenterology and Motility Association and the Asian Pacific Association of Gastroenterology. Epidemiology of uninvestigated and functional dyspepsia in Asia: facts and fiction. *J Neurogastroenterol Motil* 2011;17:235–44.
- Tack J, Talley NJ. Functional dyspepsia—symptoms, definitions and validity of the Rome III criteria. *Nat Rev Gastroenterol Hepatol* 2013;10:134–41.
- Agreus L, Borgquist L. The cost of gastro-oesophageal reflux disease, dyspepsia and peptic ulcer disease in Sweden. *Pharmacoeconomics* 2002;20:347–55.
- Stanghellini V, Tosetti C, Paternico A, *et al.* Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. *Gastroenterology* 1996;110:1036–42.
- Tack J, Piessevaux H, Coulie B, *et al.* Role of impaired gastric accommodation to a meal in functional dyspepsia. *Gastroenterology* 1998;115:1346–52.
- Tack J, Caenepeel P, Fischler B, *et al.* Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. *Gastroenterology* 2001;121:526–35.
- Vanheel H, Farré R. Changes in gastrointestinal tract function and structure in functional dyspepsia. *Nat Rev Gastroenterol Hepatol* 2013;10:142–9.
- Moayyedi P, Feltbower R, Brown J, *et al.* Effect of population screening and treatment for *Helicobacter pylori* on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group. *Lancet* 2000;355:1665–9.
- Moayyedi P, Soo S, Deeks J, *et al.* Eradication of *Helicobacter pylori* for non-ulcer dyspepsia. *Cochrane Database Syst Rev* 2006;2:CD002096.
- Mazzoleni LE, Sander GB, Francesconi CF, *et al.* *Helicobacter pylori* Eradication in Functional Dyspepsia: HEROES Trial. *Arch Intern Med* 2011;171:1929–36.
- Suzuki H, Moayyedi P. *Helicobacter pylori* infection in functional dyspepsia. *Nat Rev Gastroenterol Hepatol* 2013;10:168–74.
- Aro P, Talley NJ, Ronkainen J, *et al.* Anxiety is associated with uninvestigated and functional dyspepsia (Rome III criteria) in a Swedish population-based study. *Gastroenterology* 2009;137:94–100.
- Hsu YC, Liou JM, Liao SC, *et al.* Psychopathology and personality trait in subgroups of functional dyspepsia based on Rome III criteria. *Am J Gastroenterol* 2009;104:2534–42.
- Van Oudenhove L, Aziz Q. The role of psychosocial factors and psychiatric disorders in functional dyspepsia. *Nat Rev Gastroenterol Hepatol* 2013;10:158–67.
- Zagari RM, Law GR, Fuccio L, *et al.* Epidemiology of functional dyspepsia and subgroups in the Italian general population: an endoscopic study. *Gastroenterology* 2010;138:1302–11.
- Mahadeva S, Yadav H, Rampal S, *et al.* Risk factors associated with dyspepsia in a rural Asian population and its impact on quality of life. *Am J Gastroenterol* 2010;105:904–12.

- 19 Moayyedi P, Forman D, Braunholtz D, *et al.* The proportion of upper gastrointestinal symptoms in the community associated with *Helicobacter pylori*, lifestyle factors, and nonsteroidal anti-inflammatory drugs. Leeds HELP Study Group. *Am J Gastroenterol* 2000;95:1448–55.
- 20 Feinle-Bisset C, Azpiroz F. Dietary and lifestyle factors in functional dyspepsia. *Nat Rev Gastroenterol Hepatol* 2013;10:150–7.
- 21 Camilleri M, Stanghellini V. Current management strategies and emerging treatments for functional dyspepsia. *Nat Rev Gastroenterol Hepatol* 2013;10:187–94.
- 22 Miwa H, Ghoshal UC, Fock KM, *et al.* Asian consensus report on functional dyspepsia. *J Gastroenterol Hepatol* 2012;27:626–41.
- 23 Futagami S, Shindo T, Kawagoe T, *et al.* Migration of eosinophils and CCR2-/CD68-double positive cells into the duodenal mucosa of patients with postinfectious functional dyspepsia. *Am J Gastroenterol* 2010;105:1835–42.
- 24 Talley NJ, Walker MM, Aro P, *et al.* Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. *Clin Gastroenterol Hepatol* 2007;5:1175–83.
- 25 Shindo T, Futagami S, Hiratsuka T, *et al.* Comparison of gastric emptying and plasma ghrelin levels in patients with functional dyspepsia and non-erosive reflux disease. *Digestion* 2009;79:65–72.
- 26 Haag S, Senf W, Tagay S, *et al.* Is there any association between disturbed gastrointestinal visceromotor and sensory function and impaired quality of life in functional dyspepsia? *Neurogastroenterol Motil* 2010;22:262–e79.
- 27 Kusano M, Zai H, Shimoyama Y, *et al.* Rapid gastric emptying, rather than delayed gastric emptying, might provoke functional dyspepsia. *J Gastroenterol Hepatol* 2011;26(Suppl 3):75–8.
- 28 Turkkan E, Uslan I, Acarturk G, *et al.* Does *Helicobacter pylori*-induced inflammation of gastric mucosa determine the severity of symptoms in functional dyspepsia? *J Gastroenterol* 2009;44:66–70.
- 29 Hsu YC, Liou JM, Yang TH, *et al.* Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia: is therapeutic response predicted by Rome III subgroups? *J Gastroenterol* 2011;46:183–90.
- 30 Lee MB, Liao SC, Lee YJ, *et al.* Development and verification of validity and reliability of a short screening instrument to identify psychiatric morbidity. *J Formos Med Assoc* 2003;102:687–94.
- 31 Liou JM, Chen CC, Chang CY, *et al.* Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory *Helicobacter pylori* infection: a multicentre clinical trial. *J Antimicrob Chemother* 2013;68:450–6.
- 32 Hsu PI, Lai KH, Tseng HH, *et al.* Eradication of *Helicobacter pylori* prevents ulcer development in patients with ulcer-like functional dyspepsia. *Aliment Pharmacol Ther* 2001;15:195–201.
- 33 Talley NJ, Janssens J, Lauritsen K, *et al.* Eradication of *Helicobacter pylori* in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. *BMJ* 1999;318:833–7.
- 34 Gwee KA, Teng L, Wong RK, *et al.* The response of Asian patients with functional dyspepsia to eradication of *Helicobacter pylori* infection. *Eur J Gastroenterol Hepatol* 2009;21:417–24.
- 35 Bruley Des Varannes S, Fléjou JF, Colin R, *et al.* There are some benefits for eradicating *Helicobacter pylori* in patients with non-ulcer dyspepsia. *Aliment Pharmacol Ther* 2001;15:1177–85.
- 36 Lan L, Yu J, Chen YL, *et al.* Symptom-based tendencies of *Helicobacter pylori* eradication in patients with functional dyspepsia. *World J Gastroenterol* 2011;17:3242–7.
- 37 Thumshim M, Camilleri M, Saslow SB, *et al.* Gastric accommodation in non-ulcer dyspepsia and the roles of *Helicobacter pylori* infection and vagal function. *Gut* 1999;44:55–64.
- 38 Hojo M, Miwa H, Yokoyama T, *et al.* Treatment of functional dyspepsia with anti-anxiety or antidepressive agents: systematic review. *J Gastroenterol* 2005;40:1036–42.
- 39 Clauwaert N, Jones MP, Holvoet L, *et al.* Associations between gastric sensorimotor function, depression, somatization, and symptom-based subgroups in functional gastroduodenal disorders: are all symptoms equal? *Neurogastroenterol Motil* 2012;24:1088–e565.
- 40 Handa M, Mine K, Yamamoto H, *et al.* Esophageal motility and psychiatric factors in functional dyspepsia patients with or without pain. *Dig Dis Sci* 1999;44:2094–8.
- 41 Lacy BE, Everhart K, Crowell MD. Functional dyspepsia is associated with sleep disorders. *Clin Gastroenterol Hepatol* 2011;9:410–14.
- 42 Vege SS, Locke GR III, Weaver AL, *et al.* Functional gastrointestinal disorders among people with sleep disturbances: a population-based study. *Mayo Clin Proc* 2004;79:1501–6.
- 43 Yamawaki H, Futagami S, Shimpuku M, *et al.* Impact of sleep disorders, quality of life and gastric emptying in distinct subtypes of functional dyspepsia in Japan. *J Neurogastroenterol Motil* 2014;20:104–12.
- 44 Friedman BH. An autonomic flexibility-neurovisceral integration model of anxiety and cardiac vagal tone. *Biol Psychol* 2007;74:185–99.
- 45 Carney RM, Freedland KE, Veith RC. Depression, the autonomic nervous system, and coronary heart disease. *Psychosom Med* 2005;67(Suppl 1):S29–33.
- 46 Xiao YL, Peng S, Tao J, *et al.* Prevalence and symptom pattern of pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome III criteria. *Am J Gastroenterol* 2010;105:2626–31.
- 47 Ford AC, Bercik P, Morgan DG, *et al.* The Rome III Criteria for the Diagnosis of Functional Dyspepsia in Secondary Care Are Not Superior to Previous Definitions. *Gastroenterology* 2014;146:932–40.e1.
- 48 Maiden L. Capsule endoscopic diagnosis of nonsteroidal anti-inflammatory drug-induced enteropathy. *J Gastroenterol* 2009;44(Suppl 19):64–71.
- 49 Akhtar S. Areca nut chewing and esophageal squamous-cell carcinoma risk in Asians: a meta-analysis of case-control studies. *Cancer Causes Control* 2013;24:257–65.
- 50 Akimoto K, Inamori M, Iida H, *et al.* Does postprandial coffee intake enhance gastric emptying?: a crossover study using continuous real time 13C breath test (BreathID system). *Hepatogastroenterology* 2009;56:918–20.
- 51 Lien HC, Chen GH, Chang CS, *et al.* The effect of coffee on gastric emptying. *Nucl Med Commun* 1995;16:923–6.
- 52 Malfertheiner P, Megraud F, O'Morain CA, *et al.* Management of *Helicobacter pylori* infection—the Maastricht IV/Florence Consensus Report. *Gut* 2012;61:646–64.

**Supplementary Table 1. Risk Factors of Uninvestigated Dyspepsia and Functional Dyspepsia as Compared With Healthy Controls- Univariate Analysis**

	No dyspepsia (n=1031)	Uninvestigated Dyspepsia(n =771)			Functional dyspepsia(n=491)		
	n (%)	n (%)	OR (95%CI)	p-value	n (%)	OR (95%CI)	p-value
<b>Demographic factors</b>							
<b>Sex</b>							
Male	515(50.0)	302(39.2)	1	<0.001	146(29.7)	1	<0.001
Female	516(50.0)	469(60.8)	1.55(1.28-1.87)		345(70.3)	2.36(1.88-2.97)	
<b>Age(year)</b>							
Mean(SD)	51.79(10.69)	46(13.80)	0.96(0.95-0.97)	<0.001	45.0(13.30)	0.95(0.94-0.96)	<0.001
<b>Occupation</b>							
Unemployed	354(34.3)	250(32.4)	1		168(34.2)	1	
White-collar	372(36.1)	246(31.9)	0.94(0.75-1.18)	0.573	170(34.6)	0.96(0.74-1.25)	0.774
Blue-collar (Labor)	305(29.1)	275(35.7)	1.28(1.02-1.61)	0.037	153(31.2)	1.06(0.81-1.38)	0.684
<b>Married status</b>							
Married	885(85.8)	593(76.9)	1		367(74.7)	1	
Never married	94(9.1)	151(19.6)	2.40(1.82-3.17)	<0.001	107(21.8)	2.75(2.03-3.72)	<0.001
Divorced	32(3.1)	18(2.3)	0.84(0.47-1.51)	0.559	12(2.4)	0.90(0.46-1.78)	0.770
Married again	20(1.9)	9(1.2)	0.67(0.30-1.46)	0.325	5(1.0)	0.60(0.23-1.62)	0.315
<b>Education level</b>							
Below elementary	102(9.9)	124(16.1)	1		60(12.2)	1	
Below senior high school	252(24.4)	312(40.5)	1.02(0.75-1.39)	0.908	193(39.3)	1.30(0.90-1.89)	0.504
Above college	677(65.7)	335(43.5)	0.41(0.30-0.55)	<0.001	238(48.5)	0.60(0.42-0.85)	0.004
<b>Blood type†</b>							
A type	264(25.6)	185(27.5)	1		122(28.4)	1	
B type	223(21.6)	151(22.5)	0.97(0.73-1.28)	0.81	96(22.3)	0.93(0.68-1.29)	0.665
AB type	56(5.4)	63(9.4)	1.61(1.07-2.41)	0.022	42(9.8)	1.62(1.03-2.56)	0.037
O type	435(42.2)	273(40.6)	0.90(0.70-1.14)	0.370	170(39.5)	0.85(0.64-1.12)	0.238
<b>Lifestyle factors</b>							
<b>BMI(kg/m2)</b>							
Mean(SD)	23.52(3.19)	23.72(7.63)	1.01(0.99-1.02)	0.439	22.94(5.10)	0.96(0.93-0.99)	0.006
<b>Smoking</b>							
Never	831(80.6)	545(70.7)	1		381(77.6)	1	
Ever	200(19.4)	226(29.3)	1.72(1.38-2.14)	<0.001	110(22.4)	1.20(0.92-1.56)	0.174
<b>Alcohol</b>							

consumption							
Never	842(81.7)	558(72.4)	1		378(77.0)	1	
Ever	189(18.3)	213(27.6)	1.70(1.36-2.13)	<0.001	113(23.0)	1.33(1.02-1.73)	0.033
Betel nut chewing							
Never	1017(98.6)	683(88.6)	1		452(92.1)	1	
Ever	14(1.4)	88(11.4)	9.36(5.28-16.59)	<0.001	39(7.9)	6.27(3.37-11.66)	<0.001
Tea consumption							
Never	461(44.7)	383(49.7)	1		247(50.3)	1	
Ever	570(55.3)	388(50.3)	0.82(0.68-0.99)	0.037	244(49.7)	0.80(0.64-0.99)	0.041
Coffee consumption							
Never	545(52.9)	479(62.1)	1		297(60.5)	1	
Ever	486(47.1)	292(37.9)	0.68(0.57-0.83)	<0.001	194(39.5)	0.73(0.59-0.91)	0.005
Vegetarians							
Never	996(96.9)	724(93.9)	1		462(94.1)	1	
Ever	35(3.4)	47(6.1)	1.84(1.18-2.89)	0.007	29(5.9)	1.79(1.08-2.96)	0.024
Exercise habit							
Less/never	361(35.0)	488(63.3)	1		297(60.5)	1	
Ever	670(65.0)	283(36.7)	0.31(0.26-0.38)	<0.001	194(39.5)	0.35(0.28-0.44)	<0.001
NASIDs recent consumption							
Never	997(96.7)	598(77.6)	1		383(78.0)	1	
Ever	34(3.3)	173(22.4)	8.48(5.79-12.42)	<0.001	108(22.0)	8.27(5.53-13.37)	<0.001
Aspirin recent consumption							
Never	988(95.8)	761(98.7)	1		484(98.6)	1	
Ever	43(4.2)	10(1.3)	0.30(0.15-0.61)	0.001	7(1.4)	0.33(0.15-0.74)	0.007
Psychological factor (BSRS-5)							
I. Sleep disturbance							
No	619(60.0)	280(36.3)	1		161(32.8)	1	
Yes	412(40.0)	491(63.7)	2.64(2.17-3.19)	<0.001	330(67.2)	3.08(2.46-3.86)	<0.001
II. Anxiety							
No	727(70.5)	321(41.6)	1		169(34.4)	1	
Yes	304(29.5)	450(58.4)	3.35(2.76-4.08)	<0.001	322(65.6)	4.56(3.62-5.73)	<0.001
III. Hostility							
No	674(65.4)	376(48.8)	1		214(43.6)	1	
Yes	357(34.6)	395(51.2)	1.98(1.64-2.40)	<0.001	277(56.4)	2.44(1.96-3.04)	<0.001
IV. Depression							
No	759(73.6)	389(50.5)	1		225(45.8)	1	
Yes	272(26.4)	382(49.5)	2.74(2.25-3.34)	<0.001	266(54.2)	3.29(2.63-4.13)	<0.001

V. Inferiority							
No	891(86.4)	579(75.1)	1		366(74.5)	1	
Yes	140(13.6)	192(24.9)	2.11(1.66-2.69)	<0.001	125(25.5)	2.17(1.66-2.85)	<0.001
Other factors							
<i>H. pylori</i>							
No	652(63.2)	413(53.6)	1		295(60.1)	1	
Yes	379(36.8)	358(46.4)	1.49(1.23-1.80)	<0.001	196(39.9)	1.14(0.92-1.43)	0.235
IBS							
No	999(96.9)	620(80.4)	1		347(70.7)	1	
Yes	32(3.1)	151(19.6)	10.57(7.17-15.57)	<0.001	144(29.3)	12.96(8.67-19.37)	<0.001

OR and 95% CI calculated using univariate logistic regression model.

†Blood type was unknown in 53 with control group,99 with uninvestigated dyspepsia,61 with functional dyspepsia.

BMI, body mass index; BSRS-5, short form of Brief Symptom Rating Scale; CI, confidence interval; *H. pylori*, *Helicobacter pylori*; IBS: irritable bowel syndrome; NSAIDs, non-steroidal anti-inflammatory drugs; n, number; OR, Odds ratio; SD, standard deviation.

**Supplementary Table 2. Risk Factors of Subgroups of Functional Dyspepsia as Compared With Healthy Controls- Univariate Analysis**

	No dyspepsia (N=1031)	PDS (n=184)			EPS (n=129)			Overlap (n=169)		
	n (%)	n (%)	OR (95% CI)	p-value	n (%)	OR (95% CI)	p-value	n (%)	OR (95% CI)	p-value
<b>Demographic factors</b>										
<b>Sex</b>										
Male	515 (50.0)	55 (29.9)	1	<0.001	41 (31.8)	1	<0.001	47 (27.8)	1	<0.001
Female	516 (50.0)	129 (70.1)	2.34 (1.67-3.28)		88 (68.2)	2.14 (1.45-3.17)		122 (72.2)	2.59 (1.81-3.71)	
<b>Age</b>										
Mean (SD)	51.79 (10.69)	44 (13.83)	0.94 (0.93-0.95)	<0.001	46 (13.12)	0.95 (0.94-0.97)	<0.001	44 (12.87)	0.94 (0.93-0.95)	<0.001
<b>Occupation</b>										
Unemployed	354 (34.3)	55 (29.9)	1		39 (30.2)	1		72 (42.6)	1	
White-collar	372 (36.1)	74 (40.2)	1.28 (0.88-1.87)	0.200	46 (35.7)	1.04 (0.67-1.61)	0.860	46 (27.2)	0.61 (0.41-0.90)	0.014
Blue-collar (Labor)	305 (29.1)	55 (29.9)	1.16 (0.78-1.74)	0.471	44 (34.1)	1.19 (0.76-1.86)	0.451	51 (30.2)	0.82 (0.56-1.21)	0.325
<b>Married status</b>										
Married	885 (85.8)	123 (66.8)	1		103 (79.8)	1		134 (79.3)	1	
Never married	94 (9.1)	54 (29.3)	4.13 (2.82-6.07)	<0.001	20 (15.5)	1.74 (1.03-2.94)	0.037	31 (18.3)	2.18 (1.40-3.40)	0.001





Never	842 (81.7)	138 (75)	1	0.036	105 (81.4)	1	0.940	128 (75.7)	1	0.071
Ever	189 (18.3)	46 (25)	1.49 (1.03-2.15)		24 (18.6)	1.02 (0.64-1.63)		41 (24.3)	1.43 (0.97-2.10)	
Betel nut chewing										
Never	1017 (98.6)	174 (94.6)	1	0.001	120 (93.0)	1	<0.001	150 (88.8)	1	<0.001
Ever	14 (1.4)	10 (5.4)	4.18 (1.83-9.56)		9 (7.0)	5.45 (2.31-12.87)		19 (11.2)	9.20 (4.51-18.74)	
Tea consumption										
Never	461 (44.7)	96 (52.2)	1	0.062	65 (50.4)	1	0.223	80 (47.3)	1	0.525
Ever	570 (55.3)	88 (47.8)	0.74 (0.54-1.02)		64 (49.6)	0.80 (0.55-1.15)		89 (52.7)	0.90 (0.65-1.25)	
Coffee consumption										
Never	545 (52.9)	119 (64.7)	1	0.003	75 (58.1)	1	0.244	96 (56.8)	1	0.341
Ever	486 (47.1)	65 (35.3)	0.61 (0.44-0.85)		54 (41.9)	0.81 (0.56-1.16)		73 (43.2)	0.85 (0.61-1.18)	
Vegetarians										
Never	996 (96.9)	173 (94.0)	1	0.095	123 (95.3)	1	0.468	158 (93.5)	1	0.055
Ever	35 (3.4)	11 (6.0)	1.81 (0.90-3.63)		6 (4.7)	1.39 (0.57-3.37)		11 (6.5)	1.98 (0.98-3.98)	
Exercise habit										
Less/never	361 (35.0)	105 (57.1)	1	<0.001	80 (62.0)	1	<0.001	106 (62.7)	1	<0.001
Ever	670 (65.0)	79 (42.9)	0.41 (0.30-0.56)		49 (38.0)	0.33 (0.23-0.48)		63 (37.3)	0.32 (0.23-0.45)	

NASIDs recent consumption										
Never	997 (96.7)	151 (82.1)	1 (3.85-10.66)	<0.001	99 (76.7)	1 (5.22-15.14)	<0.001	125 (74.0)	1 (6.36-16.76)	<0.001
Ever	34 (3.3)	33 (17.9)	6.41 (3.85-10.66)		30 (23.3)	8.89 (5.22-15.14)		44 (26.0)	10.32 (6.36-16.76)	
Aspirin recent consumption										
Never	988 (95.8)	180 (97.8)	1 (0.18-1.44)	0.204	128 (99.2)	1 (0.03-1.32)	0.091	167 (98.8)	1 (0.07-1.15)	0.076
Ever	43 (4.2)	4 (2.2)	0.51 (0.18-1.44)		1 (0.8)	0.18 (0.03-1.32)		2 (1.2)	0.28 (0.07-1.15)	
Psychological factors (BSRS-5)										
I. Sleep disturbance										
No	619 (60.0)	47 (25.5)	1 (3.07-6.24)	<0.001	72 (55.8)	1 (0.82-1.72)	0.357	39 (23.1)	1 (3.43-7.32)	<0.001
Yes	412 (40.0)	137 (74.5)	4.38 (3.07-6.24)		57 (44.2)	1.19 (0.82-1.72)		130 (76.9)	5.01 (3.43-7.32)	
II. Anxiety										
No	727 (70.5)	56 (30.4)	1 (3.89-7.69)	<0.001	57 (44.2)	1 (2.08-4.38)	<0.001	53 (31.4)	1 (3.68-7.44)	<0.001
Yes	304 (29.5)	128 (69.6)	5.47 (3.89-7.69)		72 (55.8)	3.02 (2.08-4.38)		116 (68.6)	5.23 (3.68-7.44)	
III. Hostility										
No	674 (65.4)	72 (39.1)	1 (2.12-4.06)	<0.001	61 (47.3)	1 (1.46-3.04)	<0.001	74 (43.8)	1 (1.74-3.37)	<0.001
Yes	357 (34.6)	112 (60.9)	2.94 (2.12-4.06)		68 (52.7)	2.11 (1.46-3.04)		95 (56.2)	2.42 (1.74-3.37)	
IV. Depression										

No	759 (73.6)	74 (40.2)	1	<0.001	66 (51.2)	1	<0.001	79 (46.7)	1	<0.001
Yes	272 (26.4)	110 (59.8)	4.15 (3.00-5.74)		63 (48.8)	2.66 (1.84-3.86)		90 (53.3)	3.18 (2.28-4.43)	
V. Inferiority										
No	891 (86.4)	134 (72.8)	1	<0.001	99 (76.7)	1	0.004	126 (74.6)	1	<0.001
Yes	140 (13.6)	50 (27.2)	2.38 (1.64-3.44)		30 (23.3)	1.93 (1.24-3.01)		43 (25.4)	2.17 (1.47-3.21)	
Other factors										
<i>H. pylori</i>										
No	652 (63.2)	102 (55.4)	1	0.045	77 (59.7)	1	0.432	110 (65.1)	1	0.644
Yes	379 (36.8)	82 (44.6)	1.38 (1.01-1.90)		52 (40.3)	1.16 (0.80-1.69)		59 (34.9)	0.92 (0.66-1.30)	
IBS										
No	999 (96.9)	129 (70.1)	1	<0.001	96 (74.4)	1	<0.001	116 (68.6)	1	<0.001
Yes	32 (3.1)	55 (29.9)	13.31 (8.30-21.36)		33 (25.6)	10.73 (6.32-18.22)		53 (31.4)	14.26 (8.84-23.03)	

OR and 95% CI calculated using a univariate logistic regression model.

†Blood type was unknown in 53 with control group,17 with PDS, 23 with EPS,23 with overlap syndrome.

BMI, body mass index; BSRS-5, short form of Brief Symptom Rating Scale; CI, confidence interval; EPS, epigastric pain syndrome; *H. pylori*, *Helicobacter pylori*; IBS: irritable bowel syndrome; NSAIDs, non-steroidal anti-inflammatory drugs; n, number; OR, Odds ratio; PDS, postprandial distress syndrome; SD, standard deviation.